BeiGene Reports Third Quarter 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
- Nasdaq falls ahead of earnings, economic data while oil rallies
- Oil prices rise on Saudi Arabia attacks, overshadowing Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
- One dead in new attack on Saudi airport, a day after Houthi strike kills 13
- Bausch + Lomb names Appio interim CEO as Saunders departs
- Cerebras Systems hits new 52-week low on unlock concerns
- Getty Images to go private via prepackaged Chapter 11 restructuring
- Kroger (KR) To Cut Corporate Workforce By About 3,000 Over 3 Years - Bloomberg
BeiGene, Ltd. (BGNE) PT Lowered to $427 at Cowen
November 5, 2021 7:15 AM EDTCowen analyst Yaron Werber lowered the price target on BeiGene, Ltd. (NASDAQ: BGNE) to $427.00 (from $441.00) while maintaining an Outperform rating.
The analyst commented, "Revs beat in Q3 ($206M vs. our/cons $183M) due to strength from Brukinsa and Amgen and Celgene product sales.... More



